RegeneRx Pipeline

RegeneRx is a publicly traded, clinical-stage, biopharmaceutical company engaged in the design, research and development of novel peptides targeted at diseases with unmet medical needs. RegeneRx’s mission is to research and develop novel pharmaceuticals that protect and repair tissue and organ damage caused by disease, trauma or other pathology.

RegeneRx acquired the rights to a novel peptide from the NIH in 1999. This intellectual property for Thymosin Beta 4 (Tβ4) allowed the company to direct its focus on tissue protection and repair in multiple disease indications.

Learn More

Letter to Stockholders July 22, 2021 Letter to Stockholders July 22, 2021

Letter to Stockholders December 21, 2020 Letter to Stockholders December 21, 2020


January 12, 2022 RGN-259 Regulatory Update

May 14, 2021 RegeneRx JV Issues PR on Dry Eye Results with RGN-259

Latest News
Dec 17, 2021

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that the U.S. FDA has...

More >

Sign up below to receive investor news updates from RegeneRx
* Required Fields